{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["CADDD", "DFT", "EGFR inhibitor", "MD simulations", "anticancer", "docking", "semi synthesis"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36676140", "DateRevised": {"Year": "2023", "Month": "02", "Day": "01"}, "Article": {"ArticleDate": [{"Year": "2023", "Month": "01", "Day": "09"}], "Language": ["eng"], "ELocationID": ["191", "10.3390/life13010191"], "Journal": {"ISSN": "2075-1729", "JournalIssue": {"Volume": "13", "Issue": "1", "PubDate": {"Year": "2023", "Month": "Jan", "Day": "09"}}, "Title": "Life (Basel, Switzerland)", "ISOAbbreviation": "Life (Basel)"}, "ArticleTitle": "A New Anticancer Semisynthetic Theobromine Derivative Targeting EGFR Protein: CADDD Study.", "Abstract": {"AbstractText": ["A new lead compound has been designed as an antiangiogenic EGFR inhibitor that has the pharmacophoric characteristics to bind with the catalytic pocket of EGFR protein. The designed lead compound is a (para-chloro)acetamide derivative of the alkaloid, theobromine, (<b>T-1-PCPA</b>). At first, we started with deep density functional theory (DFT) calculations for <b>T-1-PCPA</b> to confirm and optimize its 3D structure. Additionally, the DFT studies identified the electrostatic potential, global reactive indices and total density of states expecting a high level of reactivity for <b>T-1-PCPA</b>. Secondly, the affinity of <b>T-1-PCPA</b> to bind and inhibit the EGFR protein was studied and confirmed through detailed structure-based computational studies including the molecular docking against EGFR<sup>WT</sup> and EGFR<sup>T790M</sup>, Molecular dynamics (MD) over 100 ns, MM-GPSA and PLIP experiments. Before the preparation, the computational ADME and toxicity profiles of <b>T-1-PCPA</b> have been investigated and its safety and the general drug-likeness predicted. Accordingly, <b>T-1-PCPA</b> was semi-synthesized to scrutinize the proposed design and the obtained in silico results. Interestingly, <b>T-1-PCPA</b> inhibited in vitro EGFR<sup>WT</sup> with an IC<sub>50</sub> value of 25.35 nM, comparing that of erlotinib (5.90 nM). Additionally, <b>T-1-PCPA</b> inhibited the growth of A549 and HCT-116 malignant cell lines with IC<sub>50</sub> values of 31.74 and 20.40 \u00b5M, respectively, comparing erlotinib that expressed IC<sub>50</sub> values of 6.73 and 16.35 \u00b5M, respectively."]}, "AuthorList": [{"Identifier": ["0000-0002-6955-2263"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Eissa", "ForeName": "Ibrahim H", "Initials": "IH"}, {"Identifier": ["0000-0003-3709-1930"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Yousef", "ForeName": "Reda G", "Initials": "RG"}, {"Identifier": ["0000-0003-0893-6703"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}], "LastName": "Elkady", "ForeName": "Hazem", "Initials": "H"}, {"Identifier": ["0000-0003-4497-5013"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Aisha A", "Initials": "AA"}, {"Identifier": ["0000-0001-6489-6035"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh 11671, Saudi Arabia."}], "LastName": "Alsfouk", "ForeName": "Bshra A", "Initials": "BA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Chemistry Department, Faculty of Science, New Valley University, El-Kharja 72511, Egypt."}], "LastName": "Husein", "ForeName": "Dalal Z", "Initials": "DZ"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biophysics Department, Faculty of Science, Cairo University, Cairo 12613, Egypt."}], "LastName": "Ibrahim", "ForeName": "Ibrahim M", "Initials": "IM"}, {"Identifier": ["0000-0002-2546-8035"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Sciences, College of Pharmacy, AlMaarefa University, Riyadh 13713, Saudi Arabia."}], "LastName": "Elkaeed", "ForeName": "Eslam B", "Initials": "EB"}, {"Identifier": ["0000-0001-8566-1980"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt."}, {"Identifier": [], "Affiliation": "Biopharmaceutical Products Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), Alexandria 21934, Egypt."}], "LastName": "Metwaly", "ForeName": "Ahmed M", "Initials": "AM"}], "GrantList": [{"GrantID": "PNURSP2022R142", "Agency": "Princess Nourah bint Abdulrahman University", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Life (Basel)", "NlmUniqueID": "101580444", "ISSNLinking": "2075-1729"}, "CoiStatement": "No conflict of interest is to be declared."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Abd El-Mageed M.M., Eissa A.A., Farag A.E.-S., Osman E.E.A. Design and synthesis of novel furan, furo [2, 3-d] pyrimidine and furo [3, 2-e][1, 2, 4] triazolo [1, 5-c] pyrimidine derivatives as potential VEGFR-2 inhibitors. Bioorganic Chem. 2021;116:105336. doi: 10.1016/j.bioorg.2021.105336.", "ArticleIdList": ["10.1016/j.bioorg.2021.105336", "34530235"]}, {"Citation": "Chaudhari P., Bari S., Surana S., Shirkhedkar A., Wakode S., Shelar S., Racharla S., Ugale V., Ghodke M. Logical synthetic strategies and structure-activity relationship of indolin-2-one hybrids as small molecule anticancer agents: An overview. J. Mol. Struct. 2021;1247:131280. doi: 10.1016/j.molstruc.2021.131280.", "ArticleIdList": ["10.1016/j.molstruc.2021.131280"]}, {"Citation": "El-Dash Y., Elzayat E., Abdou A.M., Hassan R.A. Novel thienopyrimidine-aminothiazole hybrids: Design, synthesis, antimicrobial screening, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and VEGFR-2 inhibition. Bioorganic Chem. 2021;114:105137. doi: 10.1016/j.bioorg.2021.105137.", "ArticleIdList": ["10.1016/j.bioorg.2021.105137", "34237644"]}, {"Citation": "Nicholson R.I., Gee J.M.W., Harper M.E. EGFR and cancer prognosis. Eur. J. Cancer. 2001;37:9\u201315. doi: 10.1016/S0959-8049(01)00231-3.", "ArticleIdList": ["10.1016/S0959-8049(01)00231-3", "11597399"]}, {"Citation": "Spano J.-P., Lagorce C., Atlan D., Milano G., Domont J., Benamouzig R., Attar A., Benichou J., Martin A., Morere J.-F. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann. Oncol. 2005;16:102\u2013108. doi: 10.1093/annonc/mdi006.", "ArticleIdList": ["10.1093/annonc/mdi006", "15598946"]}, {"Citation": "Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Carotenuto A., De Feo G., Caponigro F., Salomon D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366:2\u201316. doi: 10.1016/j.gene.2005.10.018.", "ArticleIdList": ["10.1016/j.gene.2005.10.018", "16377102"]}, {"Citation": "Ayati A., Moghimi S., Salarinejad S., Safavi M., Pouramiri B., Foroumadi A. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorganic Chem. 2020;99:103811. doi: 10.1016/j.bioorg.2020.103811.", "ArticleIdList": ["10.1016/j.bioorg.2020.103811", "32278207"]}, {"Citation": "Zhao L., Ciallella H.L., Aleksunes L.M., Zhu H. Advancing computer-aided drug discovery (CADD) by big data and data-driven machine learning modeling. Drug Discov. Today. 2020;25:1624\u20131638. doi: 10.1016/j.drudis.2020.07.005.", "ArticleIdList": ["10.1016/j.drudis.2020.07.005", "PMC7572559", "32663517"]}, {"Citation": "Vemula D., Jayasurya P., Sushmitha V., Kumar Y.N., Bhandari V. CADD, AI and ML in Drug Discovery: A Comprehensive Review. Eur. J. Pharm. Sci. 2022;181:106324. doi: 10.1016/j.ejps.2022.106324.", "ArticleIdList": ["10.1016/j.ejps.2022.106324", "36347444"]}, {"Citation": "Lee J.W., Maria-Solano M.A., Vu T.N.L., Yoon S., Choi S. Big data and artificial intelligence (AI) methodologies for computer-aided drug design (CADD) Biochem. Soc. Trans. 2022;50:241\u2013252. doi: 10.1042/BST20211240.", "ArticleIdList": ["10.1042/BST20211240", "PMC9022974", "35076690"]}, {"Citation": "Pandey S., Singh B.K. De-novo drug design, molecular docking and in-silico molecular prediction of AChEI analogues through CADD approaches as anti-Alzheimer\u2019s agents. Curr. Comput. Aided Drug Des. 2020;16:54\u201372. doi: 10.2174/1573409915666190301124210.", "ArticleIdList": ["10.2174/1573409915666190301124210", "PMC6967183", "30827255"]}, {"Citation": "Ramesh M., Muthuraman A. Computer-Aided Drug Discovery (CADD) Approaches for the Management of Neuropathic Pain. Curr. Top. Med. Chem. 2021;21:2856\u20132868. doi: 10.2174/1568026621666211122161932.", "ArticleIdList": ["10.2174/1568026621666211122161932", "34809547"]}, {"Citation": "Kontoyianni M., McClellan L.M., Sokol G.S. Evaluation of docking performance: Comparative data on docking algorithms. J. Med. Chem. 2004;47:558\u2013565. doi: 10.1021/jm0302997.", "ArticleIdList": ["10.1021/jm0302997", "14736237"]}, {"Citation": "Sethi A., Joshi K., Sasikala K., Alvala M. Molecular docking in modern drug discovery: Principles and recent applications. Drug Discov. Dev. New Adv. 2019;2:1\u201321."}, {"Citation": "Torres P.H., Sodero A.C., Jofily P., Silva-Jr F.P. Key topics in molecular docking for drug design. Int. J. Mol. Sci. 2019;20:4574. doi: 10.3390/ijms20184574.", "ArticleIdList": ["10.3390/ijms20184574", "PMC6769580", "31540192"]}, {"Citation": "Fan J., Fu A., Zhang L. Progress in molecular docking. Quant. Biol. 2019;7:83\u201389. doi: 10.1007/s40484-019-0172-y.", "ArticleIdList": ["10.1007/s40484-019-0172-y"]}, {"Citation": "Elzahabi H.S., Nossier E.S., Alasfoury R.A., El-Manawaty M., Sayed S.M., Elkaeed E.B., Metwaly A.M., Hagras M., Eissa I.H. Design, synthesis, and anti-cancer evaluation of new pyrido [2, 3-d] pyrimidin-4 (3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers. J. Enzym. Inhib. Med. Chem. 2022;37:1053\u20131076. doi: 10.1080/14756366.2022.2062752.", "ArticleIdList": ["10.1080/14756366.2022.2062752", "PMC9291687", "35821615"]}, {"Citation": "Nasser A.A., Eissa I.H., Oun M.R., El-Zahabi M.A., Taghour M.S., Belal A., Saleh A.M., Mehany A.B., Luesch H., Mostafa A.E. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR WT and EGFR T790M. Org. Biomol. Chem. 2020;18:7608\u20137634. doi: 10.1039/D0OB01557A.", "ArticleIdList": ["10.1039/D0OB01557A", "32959865"]}, {"Citation": "Elmetwally S.A., Saied K.F., Eissa I.H., Elkaeed E.B. Design, synthesis and anticancer evaluation of thieno [2, 3-d] pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers. Bioorganic Chem. 2019;88:102944. doi: 10.1016/j.bioorg.2019.102944.", "ArticleIdList": ["10.1016/j.bioorg.2019.102944", "31051400"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Alsfouk A.A., Husein D.Z., Ibrahim I.M., Metwaly A.M., Eissa I.H. New anticancer theobromine derivative targeting egfrwt and egfrt790m: Design, semi-synthesis, in silico, and in vitro anticancer studies. Molecules. 2022;27:5859. doi: 10.3390/molecules27185859.", "ArticleIdList": ["10.3390/molecules27185859", "PMC9500845", "36144596"]}, {"Citation": "Bonomi P. Erlotinib: A new therapeutic approach for non-small cell lung cancer. Expert Opin. Investig. Drugs. 2003;12:1395\u20131401. doi: 10.1517/13543784.12.8.1395.", "ArticleIdList": ["10.1517/13543784.12.8.1395", "12882624"]}, {"Citation": "Ou S.-H.I. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence. Crit. Rev. Oncol. Hematol. 2012;83:407\u2013421. doi: 10.1016/j.critrevonc.2011.11.010.", "ArticleIdList": ["10.1016/j.critrevonc.2011.11.010", "22257651"]}, {"Citation": "Xu X. Parallel phase 1 clinical trials in the US and in China: Accelerating the test of avitinib in lung cancer as a novel inhibitor selectively targeting mutated EGFR and overcoming T790M-induced resistance. Cancer Commun. 2015;34:1\u20133. doi: 10.1186/s40880-015-0029-3.", "ArticleIdList": ["10.1186/s40880-015-0029-3", "PMC4593347", "26152224"]}, {"Citation": "J\u00e4nne P.A., Yang J.C.-H., Kim D.-W., Planchard D., Ohe Y., Ramalingam S.S., Ahn M.-J., Kim S.-W., Su W.-C., Horn L. AZD9291 in EGFR inhibitor\u2013resistant non\u2013small-cell lung cancer. N. Engl. J. Med. 2015;372:1689\u20131699. doi: 10.1056/NEJMoa1411817.", "ArticleIdList": ["10.1056/NEJMoa1411817", "25923549"]}, {"Citation": "Traxler P., Bold G., Frei J., Lang M., Lydon N., Mett H., Buchdunger E., Meyer T., Mueller M., Furet P. Use of a pharmacophore model for the design of EGF-R tyrosine kinase inhibitors: 4-(phenylamino) pyrazolo [3, 4-d] pyrimidines. J. Med. Chem. 1997;40:3601\u20133616. doi: 10.1021/jm970124v.", "ArticleIdList": ["10.1021/jm970124v", "9357527"]}, {"Citation": "Ducray R., Ballard P., Barlaam B.C., Hickinson M.D., Kettle J.G., Ogilvie D.J., Trigwell C.B. Novel 3-alkoxy-1H-pyrazolo [3, 4-d] pyrimidines as EGFR and erbB2 receptor tyrosine kinase inhibitors. Bioorganic Med. Chem. Lett. 2008;18:959\u2013962. doi: 10.1016/j.bmcl.2007.12.035.", "ArticleIdList": ["10.1016/j.bmcl.2007.12.035", "18182285"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Alsfouk A.A., Husein D.Z., Ibrahim I.M., Alswah M., Elzahabi H.S., Metwaly A.M., Eissa I.H. A New Theobromine-Based EGFRWT and EGFRT790M Inhibitor and Apoptosis Inducer: Design, Semi-Synthesis, Docking, DFT, MD Simulations, and In Vitro Studies. Processes. 2022;10:2290. doi: 10.3390/pr10112290.", "ArticleIdList": ["10.3390/pr10112290"]}, {"Citation": "Gandin V., Ferrarese A., Dalla Via M., Marzano C., Chilin A., Marzaro G. Targeting kinases with anilinopyrimidines: Discovery of N-phenyl-N\u2019-[4-(pyrimidin-4-ylamino) phenyl] urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily. Sci. Rep. 2015;5:16750. doi: 10.1038/srep16750.", "ArticleIdList": ["10.1038/srep16750", "PMC4645160", "26568452"]}, {"Citation": "Liu Y., Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006;2:358\u2013364. doi: 10.1038/nchembio799.", "ArticleIdList": ["10.1038/nchembio799", "16783341"]}, {"Citation": "Furet P., Caravatti G., Lydon N., Priestle J.P., Sowadski J.M., Trinks U., Traxler P. Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411. J. Comput. Aided Mol. Des. 1995;9:465\u2013472. doi: 10.1007/BF00124317.", "ArticleIdList": ["10.1007/BF00124317", "8789188"]}, {"Citation": "Metwaly A.M., Lianlian Z., Luqi H., Deqiang D.J.M. Black ginseng and its saponins: Preparation, phytochemistry and pharmacological effects. Molecules. 2019;24:1856. doi: 10.3390/molecules24101856.", "ArticleIdList": ["10.3390/molecules24101856", "PMC6572638", "31091790"]}, {"Citation": "Metwaly A.M., Ghoneim M.M., Eissa I., Elsehemy I.A., Mostafa A.E., Hegazy M.M., Afifi W.M., Dou D. Traditional ancient Egyptian medicine: A review. Saudi J. Biol. Sci. 2021;28:5823\u20135832. doi: 10.1016/j.sjbs.2021.06.044.", "ArticleIdList": ["10.1016/j.sjbs.2021.06.044", "PMC8459052", "34588897"]}, {"Citation": "Husein D.Z., Hassanien R., Khamis M. Cadmium oxide nanoparticles/graphene composite: Synthesis, theoretical insights into reactivity and adsorption study. RSC Adv. 2021;11:27027\u201327041. doi: 10.1039/D1RA04754J.", "ArticleIdList": ["10.1039/D1RA04754J", "PMC9037664", "35480026"]}, {"Citation": "Wang T., Husein D.Z.J.E.S., Research P. Novel synthesis of multicomponent porous nano-hybrid composite, theoretical investigation using DFT and dye adsorption applications: Disposing of waste with waste. Environ. Sci. Pollut. Res. 2022:1\u201328. doi: 10.1007/s11356-022-20050-2.", "ArticleIdList": ["10.1007/s11356-022-20050-2", "35460480"]}, {"Citation": "Ferreira L.L., Andricopulo A.D. ADMET modeling approaches in drug discovery. Drug Discov. Today. 2019;24:1157\u20131165. doi: 10.1016/j.drudis.2019.03.015.", "ArticleIdList": ["10.1016/j.drudis.2019.03.015", "30890362"]}, {"Citation": "Norinder U., Bergstr\u00f6m C.A. Prediction of ADMET properties. ChemMedChem: Chem. Enabling Drug Discov. 2006;1:920\u2013937. doi: 10.1002/cmdc.200600155.", "ArticleIdList": ["10.1002/cmdc.200600155", "16952133"]}, {"Citation": "Johnson J.R., Cohen M., Sridhara R., Chen Y.-F., Williams G.M., Duan J., Gobburu J., Booth B., Benson K., Leighton J. Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non\u2013Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen. Clin. Cancer Res. 2005;11:6414\u20136421. doi: 10.1158/1078-0432.CCR-05-0790.", "ArticleIdList": ["10.1158/1078-0432.CCR-05-0790", "16166415"]}, {"Citation": "Abdelgalil A.A., Al-Kahtani H.M., Al-Jenoobi F.I. Profiles of Drug Substances, Excipients and Related Methodology. Volume 45. Elsevier; Amsterdam, The Netherlands: 2020. Erlotinib; pp. 93\u2013117.", "ArticleIdList": ["32164971"]}, {"Citation": "Administration U.F.a.D. TARCEVA? (Erlotinib) Package Insert.  [(accessed on 26 November 2022)]; Available online:  https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf."}, {"Citation": "Cohen M.H., Johnson J.R., Chen Y.-F., Sridhara R., Pazdur R. FDA Drug Approval Summary: Erlotinib (Tarceva) Tablets. Oncologist. 2005;10:461\u2013466. doi: 10.1634/theoncologist.10-7-461.", "ArticleIdList": ["10.1634/theoncologist.10-7-461", "16079312"]}, {"Citation": "Addeo R., Zappavigna S., Parlato C., Caraglia M. Erlotinib: Early clinical development in brain cancer. Expert Opin. Investig. Drugs. 2014;23:1027\u20131037. doi: 10.1517/13543784.2014.918950.", "ArticleIdList": ["10.1517/13543784.2014.918950", "24836441"]}, {"Citation": "Deng Y., Feng W., Wu J., Chen Z., Tang Y., Zhang H., Liang J., Xian H., Zhang S. The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer. Mol. Clin. Oncol. 2013;2:116\u2013120. doi: 10.3892/mco.2013.190.", "ArticleIdList": ["10.3892/mco.2013.190", "PMC3915642", "24649318"]}, {"Citation": "Dearden J.C. In silico prediction of drug toxicity. J. Comput. Aided Mol. Des. 2003;17:119\u2013127. doi: 10.1023/A:1025361621494.", "ArticleIdList": ["10.1023/A:1025361621494", "13677480"]}, {"Citation": "Idakwo G., Luttrell J., Chen M., Hong H., Zhou Z., Gong P., Zhang C. A review on machine learning methods for in silico toxicity prediction. J. Environ. Sci. Health Part C. 2018;36:169\u2013191. doi: 10.1080/10590501.2018.1537118.", "ArticleIdList": ["10.1080/10590501.2018.1537118", "30628866"]}, {"Citation": "Kruhlak N., Benz R., Zhou H., Colatsky T. (Q) SAR modeling and safety assessment in regulatory review. Clin. Pharmacol. Ther. 2012;91:529\u2013534. doi: 10.1038/clpt.2011.300.", "ArticleIdList": ["10.1038/clpt.2011.300", "22258468"]}, {"Citation": "HuHuber S.M., Misovic M., Mayer C., Rodemann H.-P., Dittmann K. EGFR-mediated stimulation of sodium/glucose cotransport promotes survival of irradiated human A549 lung adenocarcinoma cells. Radiother. Oncol. 2012;103:373\u2013379. doi: 10.1016/j.radonc.2012.03.008.", "ArticleIdList": ["10.1016/j.radonc.2012.03.008", "22516777"]}, {"Citation": "Yip W.L., Weyergang A., Berg K., T\u00f8nnesen H.H., Selbo P.K. Targeted Delivery and Enhanced Cytotoxicity of Cetuximab\u2212Saporin by Photochemical Internalization in EGFR-Positive Cancer Cells. Mol. Pharm. 2007;4:241\u2013251. doi: 10.1021/mp060105u.", "ArticleIdList": ["10.1021/mp060105u", "17263556"]}, {"Citation": "Taghour M.S., Mahdy H.A., Gomaa M.H., Aglan A., Eldeib M.G., Elwan A., Dahab M.A., Elkaeed E.B., Alsfouk A.A., Khalifa M.M. Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and antiproliferative evaluation. J. Enzym. Inhib. Med. Chem. 2022;37:2063\u20132077. doi: 10.1080/14756366.2022.2103552.", "ArticleIdList": ["10.1080/14756366.2022.2103552", "PMC9327782", "35875937"]}, {"Citation": "Elkaeed E.B., Eissa I.H., Elkady H., Abdelalim A., Alqaisi A.M., Alsfouk A.A., Elwan A., Metwaly A.M. A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease. Int. J. Mol. Sci. 2022;23:8407. doi: 10.3390/ijms23158407.", "ArticleIdList": ["10.3390/ijms23158407", "PMC9369012", "35955547"]}, {"Citation": "Elkaeed E.B., Youssef F.S., Eissa I.H., Elkady H., Alsfouk A.A., Ashour M.L., El Hassab M.A., Abou-Seri S.M., Metwaly A.M. Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease. Int. J. Mol. Sci. 2022;23:6912. doi: 10.3390/ijms23136912.", "ArticleIdList": ["10.3390/ijms23136912", "PMC9266348", "35805916"]}, {"Citation": "Elkaeed E.B., Yousef R.G., Elkady H., Gobaara I.M.M., Alsfouk B.A., Husein D.Z., Ibrahim I.M., Metwaly A.M., Eissa I.H. Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects. Molecules. 2022;27:4606. doi: 10.3390/molecules27144606.", "ArticleIdList": ["10.3390/molecules27144606", "PMC9317904", "35889478"]}, {"Citation": "Taghour M.S., Elkady H., Eldehna W.M., El-Deeb N.M., Kenawy A.M., Elkaeed E.B., Alsfouk A.A., Alesawy M.S., Metwaly A.M., Eissa I.H. Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: In-Vitro anticancer evaluation and in-silico studies. J. Enzym. Inhib. Med. Chem. 2022;37:1903\u20131917. doi: 10.1080/14756366.2022.2085693.", "ArticleIdList": ["10.1080/14756366.2022.2085693", "PMC9272924", "35801403"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "11", "Day": "11"}, {"Year": "2022", "Month": "12", "Day": "25"}, {"Year": "2023", "Month": "1", "Day": "6"}, {"Year": "2023", "Month": "1", "Day": "21", "Hour": "1", "Minute": "34"}, {"Year": "2023", "Month": "1", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2023", "Month": "1", "Day": "22", "Hour": "6", "Minute": "1"}, {"Year": "2023", "Month": "1", "Day": "9"}], "PublicationStatus": "epublish", "ArticleIdList": ["36676140", "PMC9867533", "10.3390/life13010191", "life13010191"]}}], "PubmedBookArticle": []}